Crossvault Capital Management LLC Purchases 605 Shares of Pfizer Inc. (NYSE:PFE)


Share on StockTwits

Crossvault Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 0.4% during the first quarter, HoldingsChannel.com reports. The firm owned 158,261 shares of the biopharmaceutical company’s stock after purchasing an additional 605 shares during the quarter. Pfizer makes up about 2.0% of Crossvault Capital Management LLC’s portfolio, making the stock its 22nd largest holding. Crossvault Capital Management LLC’s holdings in Pfizer were worth $5,734,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Baystate Wealth Management LLC boosted its position in shares of Pfizer by 0.7% in the 1st quarter. Baystate Wealth Management LLC now owns 36,227 shares of the biopharmaceutical company’s stock worth $1,313,000 after purchasing an additional 264 shares in the last quarter. Carmichael Hill & Associates Inc. raised its holdings in Pfizer by 1.9% in the 1st quarter. Carmichael Hill & Associates Inc. now owns 14,768 shares of the biopharmaceutical company’s stock worth $535,000 after acquiring an additional 270 shares during the last quarter. Detalus Advisors LLC raised its holdings in Pfizer by 1.0% in the 1st quarter. Detalus Advisors LLC now owns 27,333 shares of the biopharmaceutical company’s stock worth $990,000 after acquiring an additional 277 shares during the last quarter. Weaver Consulting Group raised its holdings in Pfizer by 5.1% in the 4th quarter. Weaver Consulting Group now owns 5,791 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 281 shares during the last quarter. Finally, Krilogy Financial LLC raised its holdings in Pfizer by 2.3% in the 1st quarter. Krilogy Financial LLC now owns 12,390 shares of the biopharmaceutical company’s stock worth $449,000 after acquiring an additional 283 shares during the last quarter. 67.36% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE PFE traded up $0.23 during mid-day trading on Tuesday, hitting $40.06. 938,611 shares of the company’s stock traded hands, compared to its average volume of 31,749,029. The company’s 50-day moving average is $37.02 and its two-hundred day moving average is $36.78. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13. The company has a market capitalization of $223.44 billion, a P/E ratio of 25.70, a PEG ratio of 2.79 and a beta of 0.70. Pfizer Inc. has a 1 year low of $31.61 and a 1 year high of $43.08.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). The business had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Thursday, May 6th. Pfizer’s dividend payout ratio is 52.88%.

A number of equities research analysts have weighed in on the stock. Berenberg Bank reiterated a “neutral” rating and set a $38.00 target price on shares of Pfizer in a research note on Tuesday, March 23rd. Mizuho dropped their target price on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, February 3rd. DZ Bank reaffirmed a “buy” rating and issued a $41.00 target price on shares of Pfizer in a report on Wednesday, February 3rd. SVB Leerink dropped their target price on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a report on Thursday, April 1st. Finally, TheStreet downgraded shares of Pfizer from a “b” rating to a “c+” rating in a report on Friday, March 5th. Eleven analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $38.47.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: Economic Bubble

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.